Decrease in Blood Pressure and Regression of Cardiovascular Complications by Angiotensin II Vaccine in Mice

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Nakagami, Futoshi ^a   Koriyama, Hiroshi ^a   Nakagami, Hironori ^b   Osako, Mariana Kiomy ^a   Shimamura, Munehisa ^b   Kyutoku, Mariko ^a   Miyake, Takashi ^b   Katsuya, Tomohiro ^a   Rakugi, Hiromi ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN II ANTIBODY; ANGIOTENSIN II PEPTIDE VACCINE; ATRIAL NATRIURETIC FACTOR; COLLAGEN TYPE 1; COLLAGEN TYPE 2; COLLAGEN TYPE 3; GAMMA INTERFERON; INTERLEUKIN 4; KEYHOLE LIMPET HEMOCYANIN; LYMPHOKINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MYOSIN HEAVY CHAIN BETA; PEPTIDE VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENZYME PHOSPHORYLATION; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; HYPERTENSION; IMMUNIZATION; INTRACELLULAR SIGNALING; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; RAT; REMISSION; SMOOTH MUSCLE FIBER; SYSTOLIC BLOOD PRESSURE; T LYMPHOCYTE; VACCINATION REACTION;

ANGIOTENSIN II; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; IMMUNIZATION; KIDNEY; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MODELS, CARDIOVASCULAR; MYOCARDIUM; RATS; RATS, INBRED SHR; T-LYMPHOCYTES; VACCINES; VENTRICULAR REMODELING;

MUS; RODENTIA;

EID: 84875477901     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060493     Document Type: Article

References (35)

1. Delavallee L, Duvallet E, Semerano L, Assier E, Boissier MC, (2010) Anti-cytokine vaccination in autoimmune diseases. Swiss Med Wkly 140: w13108.
2. Dillman RO, (2011) Cancer immunotherapy. Cancer Biother Radiopharm 26: 1-64.
3. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, et al. (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408: 982-985.
4. Schenk D, (2002) Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 3: 824-828.
5. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173-177.
6. Tissot AC, Maurer P, Nussberger J, Sabat R, Pfister T, et al. (2008) Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 371: 821-827.
7. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, et al. (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61: 46-54.
8. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F, (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14: 11-20.
9. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, et al. (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9: 448-452.
10. Broytman O, Malter JS, (2004) Anti-Abeta: The good, the bad, and the unforeseen. J Neurosci Res 75: 301-306.
11. Agadjanyan MG, Ghochikyan A, Petrushina I, Vasilevko V, Movsesyan N, et al. (2005) Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 174: 1580-1586.
12. Gardiner SM, Auton TR, Downham MR, Sharp HL, Kemp PA, et al. (2000) Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats. Br J Pharmacol 129: 1178-1182.
13. Brown MJ, Coltart J, Gunewardena K, Ritter JM, Auton TR, et al. (2004) Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond) 107: 167-173.
14. Ambuhl PM, Tissot AC, Fulurija A, Maurer P, Nussberger J, et al. (2007) A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 25: 63-72.
15. Wakerlin GE, (1958) Antibodies to renin as proof of the pathogenesis of sustained renal hypertension. Circulation 17: 653-657.
16. Katz JI, Skom JH, Wakerlin GE, (1957) Pathogenesis of spontaneous and pyelonephritic hypertension in the dog. Circ Res 5: 137-143.
17. Helmer OM, (1958) Studies on renin antibodies. Circulation 17: 648-652.
18. Frank MH, (1963) Renin in experimental renal hypertension in monkeys. Circ Res 12: 241-255.
19. Deodhar SD, Haas E, Goldblatt H, (1964) Production of Antirenin to Homologous Renin and Its Effect of Experimental Renal Hypertension. J Exp Med 119: 425-432.
20. Skeggs LT, Kahn JR, Levine M, Dorer FE, Lentz KE, (1975) Chronic one-kidney hypertension in rabbits. I. Treatment with kidney extracts. Circ Res 37: 715-724.
21. Michel JB, Guettier C, Philippe M, Galen FX, Corvol P, et al. (1987) Active immunization against renin in normotensive marmoset. Proc Natl Acad Sci U S A 84: 4346-4350.
22. Michel JB, Sayah S, Guettier C, Nussberger J, Philippe M, et al. (1990) Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin. Circulation 81: 1899-1910.
23. Downham MR, Auton TR, Rosul A, Sharp HL, Sjostrom L, et al. (2003) Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man. Br J Clin Pharmacol 56: 505-512.
24. Harris JR, Markl J, (1999) Keyhole limpet hemocyanin (KLH): a biomedical review. Micron 30: 597-623.
25. Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, et al. (2003) Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 15: 505-514.
26. Yip HC, Karulin AY, Tary-Lehmann M, Hesse MD, Radeke H, et al. (1999) Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J Immunol 162: 3942-3949.
27. Osako MK, Nakagami H, Koibuchi N, Shimizu H, Nakagami F, et al. (2010) Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ Res 107: 466-475.
28. Saito Y, Nakagami H, Morishita R, Takami Y, Kikuchi Y, et al. (2006) Transfection of human hepatocyte growth factor gene ameliorates secondary lymphedema via promotion of lymphangiogenesis. Circulation 114: 1177-1184.
29. Harding P, Yang XP, He Q, Lapointe MC, (2011) Lack of microsomal prostaglandin E synthase-1 reduces cardiac function following angiotensin II infusion. Am J Physiol Heart Circ Physiol 300: H1053-1061.
30. Morimoto T, Sunagawa Y, Kawamura T, Takaya T, Wada H, et al. (2008) The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J Clin Invest 118: 868-878.
31. Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, et al. (2009) The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 76: 546-556.
32. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, et al. (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65: 521-530.
33. Plescia OJ, (1969) The role of the carrier in antibody formation. Curr Top Microbiol Immunol 50: 78-106.
34. Gualtierotti R, Biggioggero M, Penatti AE, Meroni PL, (2010) Updating on the pathogenesis of systemic lupus erythematosus. Autoimmun Rev 10: 3-7.
35. Thomas LJ, Hammond RA, Forsberg EM, Geoghegan-Barek KM, Karalius BH, et al. (2009) Co-administration of a CpG adjuvant (VaxImmune, CPG 7909) with CETP vaccines increased immunogenicity in rabbits and mice. Hum Vaccin 5: 79-84.